“The things we hate about ourselves aren't more real than things we like about ourselves.” Ellen Goodman


Showing posts with label biomarkers. Show all posts
Showing posts with label biomarkers. Show all posts

Thursday, November 11, 2010

Optimization? What's that?

Optimization refers to the situation where you can adjust the inputs into a system according to output functions, and eventually arrive at the best solution. In therapeutic terms, it is the process of calibrating the dosage of a drug according to the clinical response so that the best dosage for the patient can be arrived at depending on the therapeutic targets and the patient's individualized response.

This is really no different from the engineering concept of a control system.

When there is an input into a particular process, and no feedback is received about the outcome....this is called an 'open loop control system'. This is probably the least ideal of all control systems. It fundamentally assumes you know everything there is to know and that the decision taken about the initial input is already adequate. This happens in therapeutics when you have fixed dose regiments, and there is no feedback about the outcome. Consider the situation in most cancer chemotherapeutic regiments. Dosage regiments are pretty much determined at the outset, and the only feedback received is if the patient has obvious toxicity which requires cessation of therapy, i.e. switch off the system! This is essentially the pharmacogenomic approach towards 'personalized medicine'.

In other scenarios, there is possibility for the operator to make adjustments to the original input based on feedback received, but this takes place independent of the original model which determined the input. This is called an "open-loop feedback control system'. Most therapeutic scenarios are of this sort, where an initial decision about a starting dosage regiment is made based on starting knowledge and assumptions about the patient. Subsequently minor adjustments to the dosage regiment can be made by the physician depending on feedback received about the patient's clinical drug response. Where there is poor ability to receive feedback about clinical drug response, the system starts to flounder and approximates the simple open-loop control system.

The open-loop feedback control system can operate with varying degrees of sophistication. It can be empirical, where the response to feedback received is relatively intuitive and based on clinical judgement. Or it can be highly deterministic where the response is determined by precise mathematical (PK or PK-PD) models.

A more sophisticated model takes into consideration the uncertainty in the system. This is called a stochastic approach.

The ideal system is that of a closed loop system where the original models determining the original input is linked to, and continually modified by new feedback received. The following diagram represents a closed loop control system with warfarin as an example.
Modified from Applied pharmacokinetics & pharmacodynamics: principles of therapeutic drug monitoring. 1992 Michael E. Burton et al.

At top-right there is a population PK-PD model of warfarin. This represents what is known about how warfarin behaves in the population in which the patient exists. Together with the clinical model at top-left, of what the desired or target INR response is, a decision about the starting dosage regiment can be made.

Subsequently, feedback is regularly received about warfarin pharmacokinetics (bottom right) and INR response (bottom left). These feedback into the original models at top right and left, and continually adjust the model so that decisions are continually taken about how the dosage regiment can be adjusted.

This is optimization... and represents what personalized medicine ought to be.

Can it be done for all drugs? Yes, it can. But it requires that there are good population PK-PD models for the drug, and good biomarkers of response that can be used as feedback. It requires resources and effort.

Above all, it will require that physicians be prepared to put in the extra effort to optimize their therapy according the the patient's real requirements.

Tuesday, September 7, 2010

Biomarkers of efficacy

Worthwhile pulling out for a read. Useful perspectives re approach for development of biomarkers for efficacy and disease progression.



The Pharmacogenomics Journal , (8 December 2009)

A multistep validation process of biomarkers for preclinical drug development
W M Freeman, G V Bixler, R M Brucklacher, C-M Lin, K M Patel, H D VanGuilder, K F LaNoue, S R Kimball, A J Barber, D A Antonetti, T W Gardner and S K Bronson

Abstract
Biomarkers that can be measured in preclinical models in a high-throughput, reproducible manner offer the potential to increase the speed and efficacy of drug development. Development of therapeutic agents for many conditions is hampered by the limited number of validated preclinical biomarkers available to gauge pharmacoefficacy and disease progression, but the validation process for preclinical biomarkers has received limited attention. This report defines a five-step preclinical biomarker validation process and applies the process to a case study of diabetic retinopathy. By showing that a gene expression panel is highly reproducible, coincides with disease manifestation, accurately classifies individual animals and identifies animals treated with a known therapeutic agent, a biomarker panel can be considered validated. This particular biomarker panel consisting of 14 genes (C1inh, C1s, Carhsp1, Chi3l1, Gat3, Gbp2, Hspb1, Icam1, Jak3, Kcne2, Lama5, Lgals3, Nppa, Timp1) can be used in diabetic retinopathy pharmacotherapeutic research, and the biomarker development process outlined here is applicable to drug development efforts for other diseases.